Trial Profile
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2023
Price :
$35
*
At a glance
- Drugs Ifetroban (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions
- Sponsors Cumberland Pharmaceuticals
- 05 Apr 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2025.
- 05 Apr 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2025.
- 09 Nov 2021 According to a Cumberland Pharmaceuticals media release, enrollment was interrupted due to the COVID-19 pandemic. However study sites have reopened and resumed screening of patients for potential participation into its studies.